WA
RVNC

Waverly Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Waverly Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,687
Closed -$56K – 408
2015
Q1 		$56K Hold
2,687
– – 0.03% 114
2014
Q4 		$46K Buy
+2,687
New +$46.9K 0.02% 127

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Waverly Advisors's RVNC Position: Q2 2015 in Review

Waverly Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2015, closing a stake of 2,687 shares — an estimated $56K sold.

Waverly Advisors first reported a position in RVNC in Q4 2014 and held it in 2 quarters. The position peaked at $56K in Q1 2015. 88 funds tracked by Wall St. Rank hold RVNC as of Q2 2015.

  • Waverly Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Waverly Advisors sold 2,687 Revance Therapeutics, Inc. shares in Q2 2015, an estimated $56K.
  • Waverly Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Waverly Advisors's Revance Therapeutics, Inc. position peaked at $56K in Q1 2015.
  • 88 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2015.

Based on Waverly Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.